Fibronectin human
| Code | Size | Price |
|---|
| FI24911 | 0.5 ml | £897.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Radioimmunoassay (RIA)
Storage:
-20°C
Documents
Further Information
Applications Description:
IFA, IHC(P), ELISA, RIA
Background:
This antibody may be used to identify fibronectin during wound healing, during tumour progression, and tumour invasion respectively. Fibronectins are glycoproteins, which occur as dimers of two 200 kDa subunits. They have binding domains for bacterial proteins, collagens, heparin-like molecules and fibrin. Cellular fibronectin is widely distributed in the stroma of malignant tumours. Human fibronectin 100%, human collagen type I, III, IV and VI <0.1% (RIA at 1:10000 dilution).
Caution:
*These antibodies are intended for in vitro research use only. They must not be used for clinical diagnostics and not for in vivo experiments in humans or animals.
Concentration:
app. 1 mg/ml
Immunogen:
Purified fibronectin from human plasma
Incubation Time:
IHC(P) 60 min at RT or 2-8°C over night
Positive Control:
Human skin
Pre-Treatment:
After de-waxing the tissue slices they are treated with 0.2% hyaluronidase (app. 300 U/mg e.g. Art. No. HYA02-50) in TBS 15 min at 37°C. There after non-specific binding is blocked by blocking serum or 3% BSA in TBS. For peroxidase systems blocking with 1% peroxide solution in TBS for 30 min at RT is recommended.
Product:
Affinity purified antibody lyophilized from phosphate buffered solution (non-sterile). Contains antimycotic substance, but no BSA and sodium azide! Reconstitute with 0.5 ml of sterile water and store aliquots at -20°C. For further dilution use appropriate antibody diluent, e.g. Art. No. PU002 for IHC.
Purification Method:
Affinity purified antibody lyophilized from phosphate buffered solution (non-sterile). Contains antimycotic substance, but no BSA and sodium azide! Reconstitute with 0.5 ml of sterile water and store aliquots at -20°C. For further dilution use appropriate antibody diluent, e.g. Art. No. PU002 for IHC.
Secondary Reagents:
Anti-rabbit IgG-conjugates, e.g. anti-rabbit IgG:FITC (Art. No. FI-1000) or anti-rabbit IgG:DyLight488 (Art. No. DI-1488).
Species Reactivity:
Human, cross-reaction with pig <0,1%
UniProt:
P02751(FINC_HUMAN)
Working Concentration:
(purified, lyophilized) IFA ? 1:80, IHC(P) ? 1:500, ELISA ? 1:200 (OD ? 500)
References
1. Heinrich L., Tissot N., Hartmann D.J., Cohen R. (2010) Comparison of the results obtained by ELISA and surface plasmon resonance for the determination of antibody affinity. J. Immunol. Methods 352, 13-22.
2. Black A.F., Bouez C., Perrier E., Schlotmann K., Chapuis F., Damour O. (2005) Optimization and characterization of an Engineered human skin equivalent. Tissue Engineering 11, 723-733.
3. Guerret S., Govignon E., Hartmann D.J., Ronfard V. (2003) Long term remodeling of a bilayered living human skin equivalent (Apligraf?) grafted onto nude mice: immunolocalization of human cells and characterization of extracellular matrix. Wound Rep. Reg.
4. De Mello-Coelho V., Villa-Verde D.M.S., Dardenne M., Savino W. (1997) Pituitary hormones modulate cell-cell interactions between thymocytes and thymic epithelial cells. J. Neuroimmunol. 76, 39-49.
2. Black A.F., Bouez C., Perrier E., Schlotmann K., Chapuis F., Damour O. (2005) Optimization and characterization of an Engineered human skin equivalent. Tissue Engineering 11, 723-733.
3. Guerret S., Govignon E., Hartmann D.J., Ronfard V. (2003) Long term remodeling of a bilayered living human skin equivalent (Apligraf?) grafted onto nude mice: immunolocalization of human cells and characterization of extracellular matrix. Wound Rep. Reg.
4. De Mello-Coelho V., Villa-Verde D.M.S., Dardenne M., Savino W. (1997) Pituitary hormones modulate cell-cell interactions between thymocytes and thymic epithelial cells. J. Neuroimmunol. 76, 39-49.